

#6
YC
2-21-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hansen et al.

Application No.: 09/872,127

Group Art Unit: 1614

Filed: June 1, 2001

Examiner: To be assigned

Confirmation No: 1919

For: Use of N-Substituted Azaheterocyclic Compounds for the Manufacture of a
Pharmaceutical Composition for the Treatment of Indications Related to Angiogenesis

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, DC 20231

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Supplemental Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. Farvard, C. et al., "Vascular Endothelial Growth Factor and Retinal Neovascularisation: A New Therapeutic Approach For Diabetic Retinopathy" Diabetes & Metabolism (Paris) Vol. 22, pages. 268-273 (1996)


2. J. Folkman., "The Influence of Angiogenesis Research on Management of Patients with Breast Cancer" Breast Cancer Research and Treatment Vol. 36., pages 109-118 (1995)
3. T. Tanaka et al., "Viral Vector-targeted Antiangiogenic Gene Therapy Utilizing an Angiostatin Complementary DNA" Cancer Research Vol. 58, pages 3362-3369 (1998)
4. M.S. Pepper., "Manipulating Angiogenesis" Arteriosclerosis, Thrombosis, and Vascular Biology Vo. 17 Part 4, page 605-619
5. WO 96/31497
6. WO 96/31498
7. WO 96/31499
8. WO 96/31481
9. WO 97/11071
10. WO 98/15548
11. WO 98/15546
12. WO 98/15550
13. WO 99/00367
14. WO 99/00376
15. DK 0367/98
16. DK 0366/98
17. DK 1472/97
18. DK 1523/98

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

The supplemental information disclosure statement submitted herewith is being filed before the mailing date of a first Office action on the merits. Therefore, no fee is due.

Date: January 15, 2002

Respectfully submitted,


Cheryl H. Agis, Reg. No. 34,086
Outside Counsel for Novo Nordisk
of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



23650

PATENT TRADEMARK OFFICE



Attorney Docket No.: 5776.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
FEB 19 2002
TECH CENTER 1600/2900

In re Application of: Hansen et al.

Serial No.: 09/872,127

Group Art Unit: 1614

Filed: June 1, 2001

Examiner: To be assigned

Confirmation No: 1919

For: Use of N-Substituted Azaheterocyclic Compounds for the Manufacture of a
Pharmaceutical Composition for the Treatment of Indications Related to Angiogenesis

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References

is being deposited with the United States Postal Service as first class mail in an envelope
addressed to:

Commissioner for Patents
Washington, DC 20231

on January 15, 2002.

Sylvia Gonzalez
(name of person mailing paper)


(signature of person mailing paper)